Protagenic Therapeutics Equity Warrant Exp 13 April 2025 PTIXW:NASDAQ

RT Quote | NASDAQ | USD
Last | 08/10/22 EDT
0.0651UNCH (UNCH)
52 week range
0.07 - 0.58
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0651
  • 52 Week High0.58
  • 52 Week High Date09/20/21
  • 52 Week Low0.07
  • 52 Week Low Date08/10/22

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0651
  • 52 Week High0.58
  • 52 Week High Date09/20/21
  • 52 Week Low0.07
  • 52 Week Low Date08/10/22
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Protagenic Therapeutics Equity Warrant Exp 13 April 2025

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Protagenic Therapeutics, Inc. is a biopharmaceutical company. The Company specializes in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-residue peptide synthetic TCAP-1. In addition, it has a portfolio of...
Garo Armen Ph.D.
Executive Chairman of the Board
Andrew Slee
Chief Operating Officer
Alexander Arrow M.D.
Chief Financial Officer
Address
149 5th Ave Rm 500
New York, NY
10010-6826
United States